TNF and rheumatoid arthritis: Although exogenous tIK treatment reduced inflammatory arthritis symptoms in the CAIA model, which is an acute RA model that is driven by the complement and the innate immune systems [44,45], Enbrel, which is a recombinant TNF-α antagonist currently used as a biopharmaceutical in RA patients [46], showed greater effectiveness than tIK protein.